ALMR · ISSUER CIK 2104204
Alamar Biosciences, Inc.
Between Jul 31, 2026 and Oct 28, 2026, 3 Alamar Biosciences, Inc. insiders reported $0.00 of open-market purchases and $29.6M of sales on SEC Form 4.
↗3 insiders filed
Original Form 4 filings from Jul 31, 2026 to Oct 28, 2026. 0 of 4 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$29.6MInsider selling
−$29.6MNet open-market
Oct 27, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 27, 202616:10 | Oct 26, 2026from Oct 23, 2026 | ALMR | 10% Owner · +6 joint | S · Sell | $30.56 | −280,458 | 1,738,295 | -14% | −$8.6M | ||
| Oct 23, 202619:35 | Oct 22, 2026from Oct 21, 2026 | ALMR | 10% Owner · +6 joint | S · Sell | $29.93 | −342,626 | 1,789,183 | -16% | −$10.3M | ||
| Oct 21, 202619:15 | Oct 20, 2026from Oct 19, 2026 | ALMR | 10% Owner · +6 joint | S · Sell | $27.35 | −217,512 | 1,851,350 | -11% | −$5.9M | ||
| Oct 19, 202616:30 | Oct 16, 2026from Oct 15, 2026 | ALMR | 10% Owner · +6 joint | S · Sell | $27.73 | −173,673 | 1,890,817 | -8% | −$4.8M | ||
| Sep 16, 202616:20 | Sep 14, 2026 | ALMR | General Counsel | A · Grant | — | +29,000 | 29,000 | New | — | ||
| Sep 3, 202616:27 | Sep 1, 2026 | ALMR | Director | A · Grant | — | +5,686 | 5,686 | New | — |